BeaconMedIC
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (?50%) Tumor PD-L1 Expression (BMIC-031)
303 0 Acute Lymphoblastic Leukemia Free
Trending
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
Is There Still a Value in Testing for PD-L1 Expression in Advanced NSCLC Today? (BMIC-005)
The FLAURA Trial: Practice-Changing Results for Patients with EGFR Mutation-Positive NSCLC (BMIC-007)
New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018)
A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Negative (<1%) Tumor PD-L1 Expression (BMIC-033)
Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034)
Could Immunotherapy Replace Neoadjuvant Chemo for Muscle-Invasive Transitional Cell Carcinoma? Highlights from ASCO 2018 (BMIC-047)
Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
My videos
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
1,201 Views
1 year ago
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)
TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)
